证券代码：301103 证券简称：何氏眼科 公告编号：2025-039 辽宁何氏眼科医院集团股份有限公司 董事会薪酬与考核委员会关于 2025 年限制性股票激励计划 激励对象名单的公示情况说明及核查意见 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 9 月 19 日召开第三届董事会第十二次会议，审议通过了《关于<辽宁何氏眼科医院集团 股份有限公司 2025 年限制性股票激励计划（草案）>及其摘要的议案》等相关议 案，具体内容详见公司于 2025 年 9 月 23 日在巨潮资讯网（www.cninfo.com.cn） 披露的相关公告。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）《深圳证 券交易所创业板股票上市规则》（以下简称"《上市规则》"）《深圳证券交易所 创业板上市公司自律监管指南第 1 号——业务办理》（以下简称"《监管指南第 1 号》"）等相关规定，公司对《2025 年限制性股票激励计划（草案）》（以下 简称"《激励计划》""本次激励计划"）激励对象的姓名和职务在公 ...

证券代码：301103 证券简称：何氏眼科 公告编号：2025-040 辽宁何氏眼科医院集团股份有限公司 关于 2025 年限制性股票激励计划内幕信息知情人 买卖公司股票情况的自查报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 9 月 19 日召开第三届董事会第十二次会议，审议通过了《关于<辽宁何氏眼科医院集团 股份有限公司 2025 年限制性股票激励计划（草案）>及其摘要的议案》等相关议 案。并于 2025 年 9 月 23 日在巨潮资讯网（www.cninfo.com.cn）上披露了相关公 告。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）《深圳证 券交易所创业板上市公司自律监管指南第 1 号——业务办理》等法律、法规及规 范性文件的相关规定，公司对 2025 年限制性股票激励计划（以下简称"本次激励 计划"）采取了充分且必要的保密措施，同时对本次激励计划的内幕信息知情人 进行了登记。公司通过向中国证券登记结算有限公司深圳分公司（以下简称"中 登深圳"）查询，对本激 ...

Group 1 - He Eye Hospital's subsidiary has signed a share subscription agreement to acquire Japan's Ido Medical, marking a significant step in its international expansion in ophthalmology [1] - The investment requires approval from multiple regulatory bodies in both China and Japan, highlighting the complexities and high barriers of cross-border medical investments [1] Group 2 - Jin Cheng Pharmaceutical's actual controller and chairman, Zhao Yeqing, received a notice of administrative penalty for violating securities laws, resulting in a fine of 3 million yuan, with Zhao personally liable for 1.5 million yuan and a four-year market ban [2] - This incident raises concerns about the company's governance and internal control, potentially impacting its reputation and market confidence [2] Group 3 - Two senior executives at Nuo Si Ge have resigned from their vice president positions but will continue to lead subsidiary companies, indicating an internal management restructuring aimed at enhancing operational efficiency and strategic execution [3] Group 4 - Haikang Pharmaceutical's subsidiary has received acceptance for an IND application for HSK36357 capsules, a new small molecule drug with independent intellectual property rights, showing significant analgesic effects and potential in treating muscular dystrophy [4] - The dual mechanism of HSK36357 could provide a new treatment option for patients with Duchenne muscular dystrophy, indicating substantial market potential if clinical validation is achieved [4] Group 5 - Changfeng Pharmaceutical has successfully listed on the Hong Kong Stock Exchange with an IPO price of 14.75 HKD per share, focusing on the research, production, and commercialization of inhalation technologies for respiratory diseases [5] - The company's stock surged over 200% on its debut, reflecting strong market recognition of its leading position in the inhalation drug sector [6]

关于使用部分超募资金注资全资子公司收购 证券代码：301103 证券简称：何氏眼科 公告编号：2025-038 辽宁何氏眼科医院集团股份有限公司 三、风险提示 1、本次对株式会社医道メディカル公司投资事项涉及海外投资，资金的汇出 尚需经过国内的发改委、商务主管部门、外汇主管部门等境内主管机关以及日本 相关政府部门的批准或备案手续，本次投资能否通过上述审批或备案程序以及通 过的时间存在不确定性。 株式会社医道メディカル 70.65%股权的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、对外投资概述 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开第三届董事会第十一次会议、2025 年 9 月 15 召开 2025 年第一次临时股 东大会，审议通过了《关于使用部分超募资金注资全资子公司收购株式会社医道 メディカル 70.65%股权的议案》。为进一步推进和提升公司国际化战略布局能力， 推动公司在医疗健康产业的创新发展，公司拟使用超募资金 4,000 万元人民币对 公司全资子公司广东横琴澳星启明国际医疗管理有限公 ...

Company Overview - He Eye Hospital Group, established on October 15, 2009, is located in Shenyang, Liaoning Province, and was listed on March 22, 2022 [1] - The company primarily provides specialized ophthalmic diagnosis and treatment services, with revenue composition as follows: Vision services 30.24%, Refractive surgery correction services 24.16%, Non-surgical treatment 20.02%, Cataract diagnosis and treatment services 13.68%, Vitreoretinal diagnosis and treatment services 8.09%, Other ophthalmic diagnosis and treatment services 3.20%, Other business income 0.61% [1] Financial Performance - As of June 30, 2025, He Eye Hospital reported operating revenue of 560 million yuan, a year-on-year decrease of 4.22%, while net profit attributable to shareholders was 44.32 million yuan, reflecting a year-on-year increase of 84.19% [2] - The company has distributed a total of 348 million yuan in dividends since its A-share listing, with 275 million yuan distributed over the past three years [3] Stock Performance - As of September 30, the stock price of He Eye Hospital increased by 2.14% to 21.03 yuan per share, with a total market capitalization of 3.323 billion yuan [1] - Year-to-date, the stock price has risen by 5.29%, with a 1.69% increase over the last five trading days, but a decline of 3.93% over the last 20 days and 3.53% over the last 60 days [1] - The number of shareholders increased by 15.03% to 10,800, while the average circulating shares per person decreased by 13.07% to 7,684 shares [2] Institutional Holdings - As of June 30, 2025, the sixth largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B (000727), holding 2.7947 million shares, a decrease of 1.7584 million shares compared to the previous period [3]

Core Viewpoint - He Eye Hospital (301103) is primarily engaging in industry investment funds rather than direct research and production activities [1] Group 1: Company Activities - The company participates as a limited partner in the establishment of the Zhaohua (Guizhou) Health Technology Industry Development Fund, which focuses on eye health [1] - The fund primarily invests in new-generation medical health, dietary nutrition, and synthetic biology sectors [1] Group 2: Future Disclosures - The company will strictly adhere to information disclosure requirements and announce any significant developments in a timely manner [1]

Core Viewpoint - He Eye Hospital experienced a decline of 1.67% in stock price on September 25, with a trading volume of 29.49 million yuan, indicating potential market concerns regarding the company's performance [1] Financing Summary - On September 25, He Eye Hospital had a financing buy-in amount of 4.36 million yuan and a financing repayment of 3.73 million yuan, resulting in a net financing buy of 0.63 million yuan [1] - The total financing and securities balance for He Eye Hospital reached 65.76 million yuan, with the financing balance accounting for 2.02% of the circulating market value, which is below the 50th percentile level over the past year, indicating a low financing position [1] - In terms of securities lending, there were no shares repaid or sold on September 25, with a remaining quantity of 100 shares and a securities lending balance of 2,065 yuan, which is above the 50th percentile level over the past year, suggesting a high securities lending position [1] Company Overview - He Eye Hospital Group, established on October 15, 2009, and listed on March 22, 2022, is located in Shenyang, Liaoning Province, and specializes in providing ophthalmic specialty diagnosis and treatment services [2] - The company's revenue composition includes: vision care services (30.24%), refractive surgery correction services (24.16%), non-surgical treatments (20.02%), cataract diagnosis and treatment services (13.68%), vitreoretinal diagnosis and treatment services (8.09%), other eye disease treatment services (3.20%), and other business income (0.61%) [2] - As of June 30, the number of shareholders increased by 15.03% to 10,800, while the average circulating shares per person decreased by 13.07% to 7,684 shares [2] Financial Performance - For the first half of 2025, He Eye Hospital reported a revenue of 560 million yuan, reflecting a year-on-year decrease of 4.22%, while the net profit attributable to shareholders was 44.32 million yuan, showing a significant year-on-year increase of 84.19% [2] Dividend Information - Since its A-share listing, He Eye Hospital has distributed a total of 348 million yuan in dividends, with 275 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, the sixth largest circulating shareholder of He Eye Hospital is Rongtong Health Industry Flexible Allocation Mixed A/B (000727), holding 2.79 million shares, which is a decrease of 1.76 million shares compared to the previous period [3]

Group 1 - The second International Civil Society Conference on Global Development Initiatives was held in Hohhot, co-hosted by the China International Exchange Promotion Association and the Inner Mongolia Autonomous Region Government, with He Eye Hospital Group invited to participate [1] - He Eye Hospital has been focusing on eye health for 30 years, leveraging innovative technology to build a comprehensive ecosystem in the eye health industry, aiming to create the "He Smart Bright City" [1] - He Eye Hospital is a member of the World Association of Eye Hospitals (WAEH) and actively participates in international training programs and foreign aid medical projects [1] Group 2 - Recently, He Eye Hospital has signed cooperation agreements with civil organizations from Malaysia, Pakistan, and Ethiopia to expand its international collaboration in public health within the eye health sector [2] - During the conference, He Eye Hospital signed a cooperation agreement with the Zambian Ministry of Health to enhance eye health services in Zambia through talent training, technology sharing, and innovative models [2] - He Eye Hospital aims to strengthen international cooperation in public health by sharing technology, exchanging talents, and providing public welfare services, contributing to the construction of a community with a shared future for mankind [2]

Core Insights - The second International Civil Society Conference on Global Development Initiative was held in Hohhot, Inner Mongolia, where He Eye Hospital was invited to showcase its international blindness prevention cooperation achievements [1][2] - He Eye Hospital aims to strengthen communication and cooperation with civil organizations worldwide in public health, leveraging technology sharing, talent exchange, and public service to create a replicable and sustainable eye health model [1] Group 1: Company Initiatives - He Eye Hospital has been deeply engaged in the eye health sector for 30 years, accumulating extensive experience in blindness prevention technologies and practices [1] - The company operates a comprehensive eye health ecosystem platform built on the "medical, education, industry, and research" model, with a strategic goal of establishing the "He Smart Light City" [1] - He Eye Hospital is a member of the World Association of Eye Hospitals (WAEH) and has played a significant role in international ophthalmology training and foreign aid medical projects [2] Group 2: International Collaborations - Recently, He Eye Hospital signed cooperation agreements with civil organizations from Malaysia, Pakistan, and Ethiopia, expanding its international public health cooperation network [2] - During the conference, a cooperation agreement was also signed with representatives from the Zambian Ministry of Health, focusing on talent training, technology sharing, and building blindness prevention models [2] - The hospital plans to utilize big data and artificial intelligence to enhance the quality of eye health services in Zambia, contributing to local capacity building [2]

Group 1 - The company held its 12th meeting of the third board of directors on September 19, 2025, with all seven directors present, and the meeting was deemed legal and effective [2][3][4] - The board approved the draft of the 2025 Restricted Stock Incentive Plan to attract and retain talented management and align interests among shareholders, the company, and key personnel [3][5][6] - The board also approved the management measures for the implementation of the 2025 Restricted Stock Incentive Plan to ensure its smooth operation and performance [5][6][7] Group 2 - The company proposed to use up to RMB 680 million of idle raised funds and up to RMB 620 million of its own funds for cash management, aiming to improve fund utilization efficiency without affecting normal operations [14][21][24] - The cash management will involve purchasing low-risk financial products, ensuring that the funds remain secure and liquid [26][28][30] - The board's decision on cash management is subject to approval at the upcoming second extraordinary general meeting of shareholders on October 20, 2025 [16][20][45] Group 3 - The company will hold its second extraordinary general meeting of shareholders on October 20, 2025, with provisions for both on-site and online voting [16][46][49] - The meeting will require a two-thirds majority vote for special resolutions related to the restricted stock incentive plan [49] - Shareholders must register for the meeting and can participate either in person or through online voting [48][50][51]